14 November 2024
News & Insights
Endpoint News | October 2022
Drug discovery biotech looking into the ‘dark’ regions of the human genome picks up a $40M+ Series A
October 2022
Nucleome Therapeutics raises oversubscribed £37.5 million Series A financing to decode the dark matter of the human genome and deliver first-in-class precision medicines
October 2021
Nature Biotechnology puts a spotlight on Nucleome's innovative platform technology that mines the non-coding part of the genome, or ‘dark matter’, and discusses why this dark genome has huge potential for drug discovery
July 2021
Dr Danuta Jeziorska, CEO and co-founder of Nucleome Therapeutics explains how the Company is Shining a light on the dark genome in MedNous, Research Strategy article
The Dark Genome Symposium | 2024 Nov
Illuminating the Dark Genome to enable drug discovery from human genetics
Heward J, Smith J, Owers L, Davidson B, James-Bott A, Repapi E, Hertweck A, Abu-Jamous B, Harrison S. Illuminating the Dark Genome to enable drug discovery from human genetics. The Dark Genome Symposium, New York, USA, 2024
The Dark Genome Symposium | 2024 Nov
High resolution genetic mapping has identified a novel disease target for rheumatoid arthritis
Hargreaves C, Jozefowska W, Lucchesi D, Maio S, Hertweck A, Repapi E, Sutton L, Owers L, Davidson B, Heward J, Stokes N, Harrison S. High resolution genetic mapping has identified a novel disease target for rheumatoid arthritis. The Dark Genome Symposium, New York, USA, 2024
NATURE GENETICS | 2021 Nov
Identification of LZTFL1 as a candidate effector gene at a COVID-19 risk locus
Downes DJ, Cross AR, Hua P, Roberts N, Schwessinger R, Cutler AJ, Munis AM, Brown J, Mielczarek O, de Andrea CE, Melero I; COvid-19 Multi-omics Blood ATlas (COMBAT) Consortium, Gill DR, Hyde SC, Knight JC, Todd JA, Sansom SN, Issa F, Davies JOJ, Hughes JR. Identification of LZTFL1 as a candidate effector gene at a COVID-19 risk locus. Nat Genet. 2021 Nov;53(11):1606-1615. doi: 10.1038/s41588-021-00955-3. Epub 2021 Nov 4. PMID: 34737427; PMCID: PMC7611960
NATURE | 2021 Jul
Defining genome architecture at base-pair resolution
Hua P, Badat M, Hanssen LLP, Hentges LD, Crump N, Downes DJ, Jeziorska DM, Oudelaar AM, Schwessinger R, Taylor S, Milne TA, Hughes JR, Higgs DR, Davies JOJ. PMID: 34108683
NATURE COMMUNICATIONS | 2021 Jan 22
High-resolution targeted 3C interrogation of cis-regulatory element organization at genome-wide scale
Downes DJ, Beagrie RA, Gosden ME, Telenius J, Carpenter SJ, Nussbaum L, De Ornellas S, Sergeant M, Eijsbouts CQ, Schwessinger R, Kerry J, Roberts N, Shivalingam A, El-Sagheer A, Oudelaar AM, Brown T, Buckle VJ, Davies JOJ, Hughes JR. PMID: 33483495
NATURE GENETICS | 2018 Dec
Single-allele chromatin interactions identify regulatory hubs in dynamic compartmentalized domains
Oudelaar AM, Davies JOJ,Schwessinger R, Liu Y, Brown JM, Downes DJ, Chiariello AM, Bianco S, Nicodemi M, Buckle VJ, Dekker J, Higgs DR, Hughes JR. PMID: 30374068
NATURE COMMUNICATION | 2019 Nov 27
A revised model for promoter competition based on multi-way chromatin interactions at the α-globin locus
Oudelaar AM, Harrold CL, Hanssen LLP, Telenius JM, Higgs DR, Hughes JR. PMID: 31776347
NUCLEIC ACIDS RESEARCH | 2017 Dec 15
Robust detection of chromosomal interactions from small numbers of cells using low-input Capture-C
Oudelaar AM, Davies JOJ, Downes DJ, Higgs DR, Hughes JR. PMID: 29186505
BIO-PROTOCOL | 2017 Dec 5
Low-input Capture-C: A Chromosome Conformation Capture Assay to Analyze Chromatin Architecture in Small Numbers of Cells
Oudelaar AM, Downes DJ, Davies JOJ, Hughes JR. PMID: 29270442
NATURE METHODS | 2017 Jan 31
How best to identify chromosomal interactions: a comparison of approaches
Davies JO, Oudelaar AM, Higgs DR, Hughes JR. PMID: 28139673
NATURE METHODS | 2015 Nov 23
Multiplexed analysis of chromosome conformation at vastly improved sensitivity
Davies JO, Telenius JM, McGowan SJ, Roberts NA, Taylor S, Higgs DR, Hughes JR. PMID: 26595209